Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021.

COVID-19 Demographics Public health policy SARS-CoV-2 Seropositivity Seroprevalence

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
30 Jan 2024
Historique:
received: 02 10 2023
revised: 04 01 2024
accepted: 04 01 2024
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: epublish

Résumé

With the spread of SARS-CoV-2 impacting upon public health directly and socioeconomically, further information was required to inform policy decisions designed to limit virus spread during the pandemic. This study sought to contribute to serosurveillance work within Northern Ireland to track SARS-CoV-2 progression and guide health strategy. Sera/plasma samples from clinical biochemistry laboratories were analysed for anti-SARS-CoV-2 antibodies. Samples were assessed using an Elecsys anti-SARS-CoV-2 or anti-SARS-CoV-2 S ECLIA (Roche) on an automated cobas e 801 analyser. Samples were also assessed via an anti-SARS-CoV-2 ELISA (Euroimmun). A subset of samples assessed via the Elecsys anti-SARS-CoV-2 ECLIA were subsequently analysed in an ACE2 pseudoneutralisation assay using a V-PLEX SARS-CoV-2 Panel 7 for IgG and ACE2 (Meso Scale Diagnostics). Across three testing rounds (June-July 2020, November-December 2020 and June-July 2021 (rounds 1-3 respectively)), 4844 residual sera/plasma specimens were assayed for anti-SARS-CoV-2 antibodies. Seropositivity rates increased across the study, peaking at 11.6 % (95 % CI 10.4 %-13.0 %) during round 3. Varying trends in SARS-CoV-2 seropositivity were noted based on demographic factors. For instance, highest rates of seropositivity shifted from older to younger demographics across the study period. In round 3, Alpha (B.1.1.7) variant neutralising antibodies were most frequently detected across age groups, with median concentration of anti-spike protein antibodies elevated in 50-69 year olds and anti-S1 RBD antibodies elevated in 70+ year olds, relative to other age groups. With seropositivity rates of <15 % across the assessment period, it can be concluded that the significant proportion of the Northern Ireland population had not yet naturally contracted the virus by mid-2021.

Sections du résumé

Background UNASSIGNED
With the spread of SARS-CoV-2 impacting upon public health directly and socioeconomically, further information was required to inform policy decisions designed to limit virus spread during the pandemic. This study sought to contribute to serosurveillance work within Northern Ireland to track SARS-CoV-2 progression and guide health strategy.
Methods UNASSIGNED
Sera/plasma samples from clinical biochemistry laboratories were analysed for anti-SARS-CoV-2 antibodies. Samples were assessed using an Elecsys anti-SARS-CoV-2 or anti-SARS-CoV-2 S ECLIA (Roche) on an automated cobas e 801 analyser. Samples were also assessed via an anti-SARS-CoV-2 ELISA (Euroimmun). A subset of samples assessed via the Elecsys anti-SARS-CoV-2 ECLIA were subsequently analysed in an ACE2 pseudoneutralisation assay using a V-PLEX SARS-CoV-2 Panel 7 for IgG and ACE2 (Meso Scale Diagnostics).
Results UNASSIGNED
Across three testing rounds (June-July 2020, November-December 2020 and June-July 2021 (rounds 1-3 respectively)), 4844 residual sera/plasma specimens were assayed for anti-SARS-CoV-2 antibodies. Seropositivity rates increased across the study, peaking at 11.6 % (95 % CI 10.4 %-13.0 %) during round 3. Varying trends in SARS-CoV-2 seropositivity were noted based on demographic factors. For instance, highest rates of seropositivity shifted from older to younger demographics across the study period. In round 3, Alpha (B.1.1.7) variant neutralising antibodies were most frequently detected across age groups, with median concentration of anti-spike protein antibodies elevated in 50-69 year olds and anti-S1 RBD antibodies elevated in 70+ year olds, relative to other age groups.
Conclusions UNASSIGNED
With seropositivity rates of <15 % across the assessment period, it can be concluded that the significant proportion of the Northern Ireland population had not yet naturally contracted the virus by mid-2021.

Identifiants

pubmed: 38304848
doi: 10.1016/j.heliyon.2024.e24184
pii: S2405-8440(24)00215-9
pmc: PMC10830527
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e24184

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.

Auteurs

Michelle K Greene (MK)

The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

Peter Smyth (P)

The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

Andrew English (A)

Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK.
School of Health and Life Sciences, Teeside University, Middlesbrough, UK.

Joseph McLaughlin (J)

Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK.

Magda Bucholc (M)

Intelligent Systems Research Centre, School of Computing, Engineering & Intelligent Systems, Ulster University, Londonderry, UK.

Janice Bailie (J)

HSC R&D Division, Public Health Agency, Belfast, UK.

Julie McCarroll (J)

HSC R&D Division, Public Health Agency, Belfast, UK.

Margaret McDonnell (M)

Department of Clinical Biochemistry, Belfast Health and Social Care Trust, Belfast, UK.

Alison Watt (A)

Regional Virology Laboratory, Belfast Health and Social Care Trust, Belfast, UK.

George Barnes (G)

Department of Clinical Biochemistry, South Eastern Health and Social Care Trust, Dundonald, UK.

Mark Lynch (M)

Department of Clinical Biochemistry, Altnagelvin Hospital, Western Health and Social Care Trust, Londonderry, UK.

Kevan Duffin (K)

Department of Clinical Biochemistry, Southern Health and Social Care Trust, Portadown, UK.

Gerard Duffy (G)

Department of Clinical Biochemistry, Northern Health and Social Care Trust, Antrim, UK.

Claire Lewis (C)

The Northern Ireland Biobank, Queen's University Belfast, Belfast, UK.

Jacqueline A James (JA)

The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
The Northern Ireland Biobank, Queen's University Belfast, Belfast, UK.
Regional Molecular Diagnostic Service, Belfast Health and Social Care Trust, Belfast, UK.

Alan W Stitt (AW)

Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.

Tom Ford (T)

Bacteriology Branch, Veterinary Sciences Division, AFBI, Belfast, UK.

Maurice O'Kane (M)

Department of Clinical Biochemistry, Altnagelvin Hospital, Western Health and Social Care Trust, Londonderry, UK.

Taranjit Singh Rai (TS)

Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK.

Anthony J Bjourson (AJ)

Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK.

Christopher Cardwell (C)

Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.

J Stuart Elborn (JS)

Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.

David S Gibson (DS)

Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK.

Christopher J Scott (CJ)

The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

Classifications MeSH